Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Restructuring (2020 - 2023)

Lifecore Biomedical, Inc. \De\ has reported Cash from Restructuring over the past 4 years, most recently at $2.6 million for Q1 2023.

  • Quarterly results put Cash from Restructuring at $2.6 million for Q1 2023, down 84.18% from a year ago — trailing twelve months through Feb 2023 was $33.1 million (down 35.96% YoY), and the annual figure for FY2024 was $1.4 million, up 119.06%.
  • Cash from Restructuring for Q1 2023 was $2.6 million at Lifecore Biomedical, Inc. \De\, up from $563000.0 in the prior quarter.
  • Over the last five years, Cash from Restructuring for LFCR hit a ceiling of $34.9 million in Q2 2021 and a floor of -$92000.0 in Q3 2021.
  • Median Cash from Restructuring over the past 4 years was $2.3 million (2021), compared with a mean of $9.5 million.
  • Biggest five-year swings in Cash from Restructuring: crashed 101.38% in 2021 and later soared 683.34% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Cash from Restructuring stood at $1.1 million in 2020, then plummeted by 42.95% to $627000.0 in 2021, then decreased by 10.21% to $563000.0 in 2022, then soared by 355.77% to $2.6 million in 2023.
  • The last three reported values for Cash from Restructuring were $2.6 million (Q1 2023), $563000.0 (Q4 2022), and $30.0 million (Q2 2022) per Business Quant data.